Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.46 |
| ▸ | HTR3A | P46098 | 1/20 | 0.46 |
| ▸ | SIRT6 | Q8N6T7 | 4/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31167860 | 0.85 | ALDH1A1 (0.54) | MAPTALDH1A1CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL14938605 | 0.84 | MAPT (0.72) | MAPTALDH1A1CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL17222820 | 0.83 | SIRT6 (0.58) | MAPTALDH1A1CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL17222813 | 0.83 | MAPT (0.52) | MAPTALDH1A1CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL18329176 | 0.83 | MAPT (0.49) | MAPTALDH1A1CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL22652226 | 0.82 | MAPT (0.51) | MAPTALDH1A1CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL3184783 | 0.81 | ALDH1A1 (0.58) | MAPTALDH1A1CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL23612032 | 0.81 | ALDH1A1 (0.47) | MAPTALDH1A1CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL31378850 | 0.81 | SIRT6 (0.60) | MAPTALDH1A1CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL30020663 | 0.81 | ALDH1A1 (0.47) | MAPTALDH1A1CYP1A2CYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3140007-A1 | METHODS OF MAKING NETUPITANT AND INTERMEDIATES THEREOF | Apicore US LLC (US) | 2017-03-15 | — | — | EP | disclosed |
| US-20170008848-A1 | METHODS OF MAKING NETUPITANT AND INTERMEDIATES THEREOF | MYLAN API US LLC | 2017-01-12 | — | — | US | disclosed |
| US-20170008848-A1 | METHODS OF MAKING NETUPITANT AND INTERMEDIATES THEREOF | MYLAN API US LLC | 2017-01-12 | — | — | US | disclosed |
| US-20170008848-A1 | METHODS OF MAKING NETUPITANT AND INTERMEDIATES THEREOF | MYLAN API US LLC | 2017-01-12 | — | — | US | disclosed |
| US-20160368875-A1 | METHODS OF MAKING NETUPITANT AND INTERMEDIATES THEREOF | MYLAN API US LLC | 2016-12-22 | — | — | US | disclosed |
| US-20160368875-A1 | METHODS OF MAKING NETUPITANT AND INTERMEDIATES THEREOF | MYLAN API US LLC | 2016-12-22 | — | — | US | disclosed |
| US-20160368875-A1 | METHODS OF MAKING NETUPITANT AND INTERMEDIATES THEREOF | MYLAN API US LLC | 2016-12-22 | — | — | US | disclosed |
| WO-2015171489-A1 | METHODS OF MAKING NETUPITANT AND INTERMEDIATES THEREOF | APICORE US LLC (US) | 2015-11-12 | — | — | WO | disclosed |
| US-20150315149-A1 | METHODS OF MAKING NETUPITANT AND INTERMEDIATES THEREOF | MYLAN API US LLC | 2015-11-05 | — | — | US | disclosed |
| US-20150315149-A1 | METHODS OF MAKING NETUPITANT AND INTERMEDIATES THEREOF | MYLAN API US LLC | 2015-11-05 | — | — | US | disclosed |
| US-20150315149-A1 | METHODS OF MAKING NETUPITANT AND INTERMEDIATES THEREOF | MYLAN API US LLC | 2015-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368875-A1 | METHODS OF MAKING NETUPITANT AND INTERMEDIATES THEREOF | NMUR1, NNT, NMUR2 | MAPT 2122/4885ALDH1A1 1015/4885CYP1A2 177/4885 |
| US-20170008848-A1 | METHODS OF MAKING NETUPITANT AND INTERMEDIATES THEREOF | NMUR1, NNT, NMUR2 | MAPT 2122/4885ALDH1A1 1015/4885CYP1A2 177/4885 |
| US-20150315149-A1 | METHODS OF MAKING NETUPITANT AND INTERMEDIATES THEREOF | NMUR1, NNT, NMUR2 | MAPT 2122/4885ALDH1A1 1015/4885CYP1A2 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.